Data / Drug companies / Sildenafil citrate
Sildenafil citrate: 24 companies and 55 products in the FDA NDC directory
Sildenafil citrate is listed in the FDA National Drug Code Directory by 24 companies, with 55 products in commercial distribution. 34 of the products (61.8%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet; tablet, film coated; film, and the newest product started marketing on June 22, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 24
- Products
- 55
- Generic (ANDA) products
- 34 (61.8%)
- Application numbers
- 15
- Routes
- Oral, Intravenous
- Brand names
- Sildenafil, Viagra, Revatio, Vybrique
- openFDA record search
- api.fda.gov
Companies that list sildenafil citrate
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Viatris Specialty LLC | 6 | tablet, film coated; injection, solution | New drug applications (NDA) | June 22, 2026 |
| Ani Pharmaceuticals, Inc. | 4 | tablet; for suspension | Generic drugs (ANDA) | August 29, 2023 |
| Ibsa Pharma Inc. | 4 | film | New drug applications (NDA) | February 15, 2026 |
| Pfizer Laboratories Div Pfizer Inc | 4 | tablet, film coated | New drug applications (NDA) | June 3, 2005 |
| Yaral Pharma Inc. | 4 | film | New drug applications (NDA) | February 15, 2026 |
| Mylan Pharmaceuticals Inc. | 3 | tablet, film coated | Authorized generics (NDA) | December 1, 2017 |
| Nivagen Pharmaceuticals, Inc. | 3 | tablet | Generic drugs (ANDA) | June 16, 2021 |
| NorthStar RxLLC | 3 | tablet | Generic drugs (ANDA) | February 24, 2026 |
| PD-Rx Pharmaceuticals, Inc. | 3 | tablet | Generic drugs (ANDA) | June 16, 2021 |
| Proficient Rx LP | 3 | tablet | Generic drugs (ANDA) | September 4, 2020 |
| Umedica Laboratories USA Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | February 15, 2026 |
| A-S Medication Solutions | 2 | tablet | Generic drugs (ANDA) | September 4, 2020 |
| Advanced Rx of Tennessee, LLC | 2 | tablet | Generic drugs (ANDA) | March 20, 2025 |
| Aphena Pharma Solutions - Tennessee, LLC | 1 | tablet | Generic drugs (ANDA) | February 24, 2026 |
| Ascend Laboratories, LLC | 1 | powder, for suspension | Generic drugs (ANDA) | November 29, 2019 |
| Asclemed USA, Inc. | 1 | tablet | Generic drugs (ANDA) | November 6, 2012 |
| Aurobindo Pharma Limited | 1 | powder, for suspension | Generic drugs (ANDA) | December 23, 2022 |
| Eugia US LLC | 1 | injection, solution | Generic drugs (ANDA) | April 1, 2015 |
| Novadoz Pharmaceuticals LLC | 1 | powder, for suspension | Generic drugs (ANDA) | February 14, 2022 |
| NuCare Pharmaceuticals,Inc. | 1 | tablet, film coated | Generic drugs (ANDA) | October 12, 2018 |
| Preferred Pharmaceuticals Inc. | 1 | tablet | Generic drugs (ANDA) | January 20, 2025 |
| Proficient Rx LP | 1 | tablet | Generic drugs (ANDA) | June 16, 2021 |
| Zydus Lifesciences Limited | 1 | powder, for suspension | Generic drugs (ANDA) | October 27, 2022 |
| Zydus Pharmaceuticals USA Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | October 27, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 23 | 41.8% |
| Tablet, film coated | 15 | 27.3% |
| Film | 8 | 14.5% |
| Powder, for suspension | 6 | 10.9% |
| Injection, solution | 2 | 3.6% |
| For suspension | 1 | 1.8% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 34 | 61.8% |
| New drug applications (NDA) | 18 | 32.7% |
| Authorized generics (NDA) | 3 | 5.5% |
Pharmacologic classes
| Class | Products |
|---|---|
| Phosphodiesterase 5 Inhibitor | 55 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.